June 5th, 2009
Guest: Katie Wilhoit, Oppenheimer Wolff & Donnelly
We loved this interview. Katie is a good friend and former colleague of G, has done IP litigation in the past, worked at Travelers Insurance as a claims attorney (in their IP division!) and now focuses on insurance coverage counseling and litigation. She loves insurance! So who better to chat with on the strange intersection of intellectual property and insurance. A myth she busted - there is no insurance coverage for IP litigation. Wrong - there can be. You gotta read your policy. And you have to be creative and persistent.
We talk about the types of insurance that might cover IP, what to do when you have a possible claim, and strategies for working with insurers. We also briefly discuss a recent case from the Minnesota Supreme Court (General Casualty Co. of WI v. Hobbit Travel) that held that trademark infringement claims trigger ”advertising injury” provisions of insurance policies (good news for those sued for trademark infringement). Give a listen. All comments/questions are welcome.
Category: Litigation | 0 Comments |
May 21st, 2009
Guest: Abel de la Rosa, Ph.D - Pharmasset, Inc.
The headlines tell it all: Pfizer Buys Wyeth for $68B; Roche Acquires Genentech for $46.8B. Big Pharma companies are buying each other and consolidating. What will be the future of smaller pharma and biotech companies? How will innovative start-up ventures survive? Where will new research and development come from? BP-G Radio explores the answers to these questions and more with our guest, Abel De La Rosa, Ph.D. In this episode, Dr. De La Rosa brings his vast experience and knowledge of business, science and intellectual property to discuss some of the Big Pharma deals and how they will affect the future of the industry. He also discusses the plight of the small innovator companies and how they will fare in these difficult economic times.
Dr. De La Rosa is currently Senior Vice President, Business Development & Scientific Affairs at Pharmasset, Inc. (NASDAQ: VRUS) and has been with them since 2002. Our guest has held both scientific and business positions at several pharma and biotech companies. Most notably, while at Visible Genetics Inc. he was responsible for the development, transfer and improvement of products, including TRUGENE HIV-1 v1.0 Genotyping Test(r) and other sequencing-based assays for HCV and HBV. He is an inventor and author on several U.S. patents and publications relating to molecular diagnostic methods and techniques for infectious diseases and cancer.
And he loves what he does (give a listen - we need this kind of enthusiasm).
Category: Uncategorized | 0 Comments |
March 20th, 2009
A few shows ago, we spoke with popular mystery writer David Fulmer about publishing deals – good ones, bad ones and how to tell the difference. But of course, publishing deals are not something you typically you learn about in your advanced writing seminar in college. There you learn your craft. How to peddle your craft (assuming you have craft) is a different proposition altogether. To sell what you’ve got, you need help – an agent. Preferably one from New York (where all the big publishing houses are). And really, you should get one from Midtown Manhattan.
Of course, agents are like publishing deals – there are good ones and bad ones. Some who will pound the pavement and work the phone to get you a deal. And others who will sign you up – and do nothing. Or, even worse, charge you to read your book and still do nothing (David says: never pay anyone to read your book). You need an agent who is ethical, industrious and focused on your subject matter (children’s, mysteries, travel, etc.) if you want results. So get personal referrals, do meticulous research and interview anyone you are thinking about working with in depth. Oh yeah, the agent should be connected. As in they go to the same bars and cafes the editors go to. Do you know where they go? Better get an agent.
Category: Uncategorized | 0 Comments |